The future of autologous stem cell transplantation in myeloma-Reference-Cited by-同舟云学术

The future of autologous stem cell transplantation in myeloma

Published:2014-07-17 Issue:3 Volume:124 Page:328-333
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

van Rhee Frits¹^ORCID,Giralt Sergio²,Barlogie Bart¹

Affiliation:

1. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and

2. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Abstract

Abstract Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/3/328/1464885/328.pdf

Reference50 articles.

1. How I treat multiple myeloma in younger patients.;Stewart;Blood,2009

2. Approach to the treatment of multiple myeloma: a clash of philosophies.;Rajkumar;Blood,2011

3. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.;Barlogie;Br J Haematol,2006

4. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.;Martinez-Lopez;Blood,2011

5. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.;van de Velde;Haematologica,2007

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience;Cancer Medicine;2024-06

2. Incidence of chronic renal injury in patients undergoing autologous stem cell transplant therapy;Internal Medicine Journal;2022-10-10

3. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?;Frontiers in Oncology;2022-08-18

4. Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model;HemaSphere;2022-08

5. Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT;Frontiers in Oncology;2022-05-18